Testosterone, tissue factor inhibition and vascular aging

References
1 Herrera MD, Mingorance C, Rodríguez-Rodríguez R. et al. Endothelial dysfunction and aging: An update. Ageing Res Rev. 2009 epub ahead of print.
2 Andreotti F, Marchese N. Women and coronary disease. Heart 2008; 94: 108-116.
3 Haddad RM, Kennedy CC, Caples SM. et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 29-39.
4 Agledahl I, Brodin E, Svartberg J. et al. Impact of long term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. Thromb Haemost 2009; 102: 945-950.
5 Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogenandrogen paradox. J Clin Endocrinol Metab 2005; 90: 2708-2711.
6 Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2008; 28: 233-242.
7 Bevilacqua MP, Pober JS, Wheeler ME. et al. Inter-leukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. Am J Pathol 1985; 121: 394-403.
8 Morange PE, Renucci JF, Charles MA. et al. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost 2001; 85: 999-1003.
9 Diver MJ. Laboratory measurement of testosterone. Front Horm Res 2009; 37: 21-31.
10 Hammes A, Andreassen TK, Spoelgen R. et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005; 122: 751-762.
11 Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 2002; 16: 2181-2187.
12 Isidori AM, Giannetta E, Greco EA. et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-293.
13 Jones RD, Pugh PJ, Jones TH. et al. The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action?. Br J Pharmacol 2003; 138: 733-744.
14 Malkin CJ, Pugh PJ, Jones RD. et al. Testosterone as a protective factor against atherosclerosis-immunomodulation and influence upon plaque development and stability. J Endocrinol 2003; 178: 373-380G.
15 Jin H, Lin J, Fu L. et al. Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. Biochem Cell Biol 2007; 85: 246-251.
16 Ferenchick GS, Hirokawa S, Mammen EF. et al. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49: 282-288.
17 Roberts MD, Dalbo VJ, Hassell SE. et al. The expression of androgen-regulated genes before and after a resistance exercise bout in younger and older men. J Strength Cond Res 2009; 23: 1060-1067.